Resources for Patients and their Families

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Brief Summary

This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery. PXD101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Tracking Information
First Received DateAugust 16, 2006
Last Changed DateMarch 21, 2018
Start DateJune 2006
Actual Primary Completion DateMarch 2009
Primary Outcome Measures

Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee [Time Frame: Up to 3 years]

Secondary Outcome Measures

Overall Survival [Time Frame: Up to 3 years]

Progression-free Survival [Time Frame: Up to 3 years]

Toxicity Profile [Time Frame: Up to 3 years]

Apoptosis by TUNEL Assay [Time Frame: At baseline]

Histone Acetylation by IHC and Western Blotting [Time Frame: At baseline and at 4 hours after last dose of PXD101 on day 5]

Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Advanced Malignant Mesothelioma
  • Epithelial Mesothelioma
  • Recurrent Malignant Mesothelioma
  • Sarcomatous Mesothelioma
  • Drug: belinostat
  • Other: laboratory biomarker analysis
Study Arms / Comparison Groups1 / 0
Detailed Description


I. Determine the objective response rate in patients with unresectable malignant pleural mesothelioma (MPM) treated with PXD101.


I. Determine the overall survival and time to progression in these patients. II. Assess the toxicities associated with this drug in these patients. III. Perform molecular correlative studies on tumor tissue (optional) and peripheral blood (required) and identify potential predictive markers for response.


Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection during course 1 of treatment for biomarker correlative studies. Fetal hemoglobin (hemoglobin F) levels are measured via reverse transcriptase-polymerase chain reaction as a potential predictive marker for response.

After completion of study treatment, patients are followed periodically.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment13
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Histologically or cytologically confirmed malignant pleural mesothelioma (MPM) of any of the following subtypes:

- Epithelial

- Sarcomatoid

- Mixed

- Have received only 1 prior systemic chemotherapy regimen for advanced mesothelioma

- Prior intrapleural cytotoxic agents (including bleomycin) not considered systemic chemotherapy

- Patients who are not candidates for combination chemotherapy are eligible even if they have not received prior chemotherapy

- Unresectable disease

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

- The sole site of measurable disease must not be located within the radiotherapy port

- No known brain metastases

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Life expectancy > 3 months

- WBC >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelet count >= 100,000/mm^3

- Bilirubin normal

- AST/ALT =< 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance >= 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-barrier contraception for 1 week before, during, and for >= 2 weeks after completion of study treatment

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101

- No symptomatic congestive heart failure

- No congestive heart failure related to primary cardiac disease

- No unstable angina pectoris

- No cardiac arrhythmia

- No condition requiring anti-arrhythmic therapy

- No uncontrolled hypertension

- No myocardial infarction within the past 6 months

- No ischemic or severe valvular heart disease

- No ongoing or active infection

- No marked baseline prolongation of QT/QTc interval

- No repeated QTc interval > 500 msec

- No long QT syndrome

- No other significant cardiovascular disease

- No other uncontrolled intercurrent illness

- No psychiatric illness or social situation that would preclude study compliance

- Recovered from prior therapy

- No prior valproic acid or other known histone deacetylase (HDAC) inhibitor

- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- More than 3 weeks since prior radiation therapy

- No concurrent medication that may cause torsade de pointes

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies

Administrative Information
Responsible PartySponsor
SponsorNational Cancer Institute (NCI)
Verification DateMarch 2018
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Fall 2018 Mesothelioma Cancer Alliance Scholarship Winner Darwin Arias

Prognosis of Mesothelioma Without Treatment

Asbestos Is No Laughing Matter

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: